Piramal Chief Says New Clinical-Trial Rules Discourage Foreign Investment
This article was originally published in PharmAsia News
Executive Summary
The head of Piramal Healthcare says added restrictions on India-based clinical trials will serve only to discourage foreign investment in the nation's pharmaceutical industry.